BEGAIN Inhibitors
BEGAIN inhibitors utilize a spectrum of biochemical mechanisms to impede the activity of BEGAIN by intricately manipulating cellular signaling pathways that control its function. These inhibitors are not uniform in their action; instead, they target various nodes within signaling cascades that BEGAIN is reliant on for its activity. For example, some compounds specifically inhibit kinases that would typically phosphorylate BEGAIN, blocking the conformational changes required for its activity. Other inhibitors disrupt the PI3K/Akt and mTOR pathways, which could be essential for the functional regulation of BEGAIN, leading to a decrease in its activity due to the dampened downstream signaling.
Further intricacy is observed with inhibitors targeting the MEK/ERK pathway and the JNK signaling pathway, which could attenuate BEGAIN activity due to its regulation by these pathways. Inhibition of p38 MAPK also results in decreased BEGAIN function given BEGAIN's activity is modulated through this specific pathway. Additionally, compounds that inhibit Akt present a reduction in BEGAIN activity, as do inhibitors of cyclin-dependent kinases. Moreover, targeting the EGFR pathway can reduce BEGAIN activity by limiting the downstream signaling events that lead to its activation. Lastly, proteasome inhibitors can indirectly diminish BEGAIN activity by causing an accumulation of regulatory proteins that suppress BEGAIN, highlighting the diverse range of inhibitors that are able to reduce BEGAIN's functional activity.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $153.00 $396.00 | 113 | |
Staurosporine is a potent inhibitor of protein kinases. By inhibiting certain kinases that phosphorylate BEGAIN, it can prevent BEGAIN from achieving a functional conformation, thereby reducing its activity. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is an inhibitor of PI3K/Akt pathway. BEGAIN, through its interactions within the cell, may be affected by alterations in this pathway, leading to decreased signaling and reduced activity. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin inhibits mTOR, which is involved in cell growth and proliferation. Downregulation of mTOR activity could decrease the functional activity of BEGAIN if BEGAIN is involved in these cellular processes. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is a p38 MAPK inhibitor. If BEGAIN's activity is modulated through the p38 MAPK pathway, inhibition of this pathway would lead to decreased BEGAIN function. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of JNK signaling. Inhibition of JNK could decrease BEGAIN activity if BEGAIN is a downstream effector of JNK signaling. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is a PI3K inhibitor. By inhibiting PI3K, it can alter cell survival and growth signals that may indirectly lead to a decrease in BEGAIN activity if BEGAIN's function is PI3K-dependent. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 is an inhibitor of MEK, which indirectly affects ERK signaling. If BEGAIN requires ERK activity for its function, PD98059 would lead to a decrease in BEGAIN activity. | ||||||
Triciribine | 35943-35-2 | sc-200661 sc-200661A | 1 mg 5 mg | $104.00 $141.00 | 14 | |
Triciribine is an Akt inhibitor. If BEGAIN is involved in pathways that are downstream of Akt, then its activity would be decreased by blocking Akt signaling. | ||||||
Roscovitine | 186692-46-6 | sc-24002 sc-24002A | 1 mg 5 mg | $94.00 $265.00 | 42 | |
Roscovitine is a cyclin-dependent kinase inhibitor. If BEGAIN is regulated by the cell cycle, inhibition of CDKs could lead to reduced BEGAIN activity. | ||||||
Gefitinib | 184475-35-2 | sc-202166 sc-202166A sc-202166B sc-202166C | 100 mg 250 mg 1 g 5 g | $63.00 $114.00 $218.00 $349.00 | 74 | |
Gefitinib is an EGFR inhibitor. If BEGAIN functions downstream of EGFR signaling, then inhibiting EGFR would reduce BEGAIN activity by decreasing downstream signaling events. | ||||||